文献速递其他结缔组织病

特发性炎性肌病治疗反应相关因素:一项注册登记研究

Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A Registry-Based Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-02-12

该注册登记研究纳入156例新诊断特发性炎性肌病患者,评估自身抗体分组与ACR/EULAR 2016应答标准之间的关联。1年后总体中位改善评分为27.5,自身抗体分组间总改善评分无差异,但皮肌炎特异性自身抗体与中度应答相关(OR 4.12,95%CI 1.2-16.5);吞咽困难、症状至诊断时间及初始糖皮质激素剂量为1年应答的显著预测因素。

要点

  • 皮肌炎特异性自身抗体患者较血清阴性组更易达中度应答(OR 4.12)。
  • 吞咽困难、较短诊断延迟和积极初始免疫抑制治疗与更高1年应答率相关。
  • 自身抗体分组间总改善评分未见差异。

核心结论

  • 皮肌炎特异性自身抗体患者相比其他自身抗体分组获得更好的应答水平。
  • 吞咽困难、较短的症状至诊断时间及积极的初始免疫抑制治疗与1年更高应答率相关,且不受自身抗体状态影响。

研究设计与样本

  • 基于电子注册登记纵向随访新诊断特发性炎性肌病患者,评估自身抗体定义分组与ACR/EULAR 2016应答标准改善之间的关联。
  • 共识别156例患者,其中111例(71%)任一检测自身抗体阳性,90%基线接受糖皮质激素治疗,78%在随访某时点接受免疫抑制药物。

主要发现

  • 从索引日期起1年后,总体中位改善评分为27.5(四分位距10-51)。
  • 自身抗体定义分组间总改善评分未观察到差异。
  • 总体62%(n=96)达最小应答,38%(n=60)达中度应答,19%(n=30)达重大应答。
  • 皮肌炎特异性自身抗体与中度应答相关,对比血清阴性组(参照),比值比4.12(95%置信区间1.2-16.5)。
  • 吞咽困难、症状发作至诊断时间及初始糖皮质激素剂量为1年随访后应答的显著预测因素。

关键数值与推荐

  • 应答评估采用ACR/EULAR 2016应答标准。
  • 皮肌炎特异性自身抗体与中度应答的比值比为4.12(95%置信区间1.2-16.5)。

临床怎么用

  • 对皮肌炎特异性自身抗体阳性患者可预期更高应答水平。
  • 关注吞咽困难、缩短诊断延迟及积极初始免疫抑制治疗可能改善1年应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify predictors of response to immunosuppressive therapy after 1 year, with a focus on autoantibodies, in patients newly diagnosed with idiopathic inflammatory myopathies (IIM) followed longitudinally in an electronic registry. METHODS: We assessed the association between autoantibody-defined groups and improvement according to American College of Rheumatology/European Alliance of Associations for Rheumatology 2016 response criteria. RESULTS: We identified 156 patients; of those, 111 (71%) were positive for any autoantibody tested, 90% received glucocorticoid treatment at baseline, and 78% received immunosuppressive drugs at some follow-up point. After 1 year from the index date, the overall median improvement score was 27.5 (interquartile range 10-51). No differences were observed in the total improvement score between the autoantibody-defined groups. Overall, 62% of patients (n = 96) showed a minimal response, 38% (n = 60) achieved a moderate response, and 19% (n = 30) achieved a major response. Regarding the different levels of response, dermatomyositis-specific autoantibodies were associated with a moderate response versus the seronegative group (reference), odds ratio 4.12 (95% confidence interval 1.2-16.5). In addition, dysphagia, time from symptom onset to diagnosis, and initial glucocorticoid dose were significant predictors of response after 1 year of follow-up. CONCLUSION: Patients with DM-specific autoantibodies achieved better levels of response compared to other autoantibody-defined groups. Dysphagia, a shorter time span from symptom onset to diagnosis, and intensive initial immunosuppressive treatment were associated with a higher response rate after 1 year of pharmacologic treatment from the index date, regardless of autoantibody status.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Espinosa-Ortega F, Holmqvist M, Dastmalchi M, et al. Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A Registry-Based Study. Arthritis Care Res (Hoboken). 2022. PMID: 33105033. doi:10.1002/acr.24498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。